HENLIUS(02696),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02696 HENLIUS

Market Closed 07-24 16:08:05

56.100

-1.500

-2.60%

High58.250	Low55.900	Vol410.91K
Open57.600	D1 Closing57.600	Amplitude4.08%
Mkt Cap30.57B	Tradable Cap19.52B	Total Shares545.00M
T/O23.26M	T/O Rate0.12%	Tradable Shares348.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"02696","market":"HK","secType":"STK","nameCN":"HENLIUS","latestPrice":56.1,"timestamp":1784880485006,"preClose":57.6,"halted":0,"volume":410913,"delay":0,"changeRate":-0.026041666666666664,"floatShares":348000000,"shares":545000000,"eps":1.7475631377238936,"marketStatus":"Market Closed","change":-1.5,"latestTime":"07-24 16:08:05","open":57.6,"high":58.25,"low":55.9,"amount":23260580,"amplitude":0.040799,"askPrice":56.1,"askSize":2400,"bidPrice":56,"bidSize":8600,"shortable":3,"etf":0,"ttmEps":1.7480053483484428,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1785115800000},"marketStatusCode":7,"adr":0,"listingDate":1569340800000,"exchange":"SEHK","adjPreClose":57.6,"openAndCloseTimeList":[[1784856600000,1784865600000],[1784869200000,1784880000000]],"volumeRatio":0.7212938010941887,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02696","defaultTab":"news","newsList":[{"id":"2653078918","title":"Shanghai Henlius Biotech (SEHK:2696) Advances Pipeline As Fair Value Questions Grow","url":"https://stock-news.laohu8.com/highlight/detail?id=2653078918","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653078918?lang=en_us&edition=fundamental","pubTime":"2026-07-22 02:33","pubTimestamp":1784658838,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech (SEHK:2696) has moved into focus after dosing the first patient in an international multicenter phase 1 trial of its nivolumab biosimilar HLX18 for multiple resected solid tumors.\nSee our latest analysis for Shanghai Henlius Biotech.\nDespite the clinical progress, Shanghai Henlius Biotech’s share price has been under pressure in recent months, with a 30 day share price return of down 5.79% and a 90 day share price return of down 28.49%. The 3 year total shareholder...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2696/shanghai-henlius-biotech-shares/news/shanghai-henlius-biotech-sehk2696-advances-pipeline-as-fair","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2696/shanghai-henlius-biotech-shares/news/shanghai-henlius-biotech-sehk2696-advances-pipeline-as-fair","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4588","VGFPF","HK0000306701.USD","FEBU","DECU","GXDW","BK4581","DCF","HK0000306685.HKD","BK4585","HK0000320264.USD","RGLO","02696","XBI","PMDE","HK0000320223.HKD","JOYT","VOTE","HK0000165453.HKD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652289657","title":"Shanghai Henlius Biotech Grants 4.13 Million Share Options at HK$ 62.28 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=2652289657","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652289657?lang=en_us&edition=fundamental","pubTime":"2026-07-17 22:27","pubTimestamp":1784298439,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech grants 4.13 million share options at HK$ 62.28 eachShanghai Henlius Biotech set new equity awards, granting 4,130,000 H-share options to 27 participants, grant date July 17, 2","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260717:nNDL5D1CfG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1230","BK1161","02696","HK0000320264.USD","HK0000306701.USD","HK0000165453.HKD","HK0000306685.HKD","00656","HK0000320223.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651434364","title":"Henlius Biotech Doses First Patient in Tumor Drug Trial in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2651434364","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651434364?lang=en_us&edition=fundamental","pubTime":"2026-07-16 18:17","pubTimestamp":1784197023,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech (HKG:2696) dosed the first patient in a phase 1 clinical study of HLX18, according to a Thursday Hong Kong bourse filing.The drug is being tested in patients with multiple resected solid tumors in Mainland China.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02696","XBI","HK0000306685.HKD","HK0000320223.HKD","HK0000165453.HKD","HK0000306701.USD","HK0000320264.USD","BK4585","BK4581","BK1161","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172209298","title":"Henlius doses first patient in global Phase 1 trial of nivolumab biosimilar HLX18 for multiple solid tumours","url":"https://stock-news.laohu8.com/highlight/detail?id=1172209298","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172209298?lang=en_us&edition=fundamental","pubTime":"2026-07-16 16:44","pubTimestamp":1784191463,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech, Inc. (Henlius, 02696) has initiated patient dosing in an international, multicentre Phase 1 clinical study evaluating its independently developed nivolumab biosimilar HLX18...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651430491","title":"Chinese Drugmakers with Big Ambitions Struggle to Recruit Staff for Global Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2651430491","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651430491?lang=en_us&edition=fundamental","pubTime":"2026-07-16 07:00","pubTimestamp":1784156400,"startTime":"0","endTime":"0","summary":"ANALYSIS-Chinese drugmakers with big ambitions struggle to recruit staff for global expansionDrug development from Chinese companies has grown significantly over the past two decadesEfforts to expand ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nL6N42V0LG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1328615791.USD","BK0183","LU1580142542.USD","LU1997245094.SGD","LU0405327494.USD","BK0028","BK0060","HK0000320223.HKD","LU2580892862.HKD","LU1655091616.SGD","LU2289578879.USD","LU2097828714.EUR","BK0196","02696","HK0000306685.HKD","LU2328871848.SGD","LU2495084118.USD","BK0188","00656","HK0000306701.USD","LU2097828557.USD","BK1161","LU1255011170.USD","LU2097828805.USD","LU1146622755.USD","688185","LU2097828631.EUR","LU1820825898.SGD","LU2097828474.EUR","LU0405327148.USD","BK1230","LU1064131003.USD","600276","BK0239","LU1969619763.USD","LU1997244956.HKD","LU1064130708.USD","LU2580892789.USD","HK0000165453.HKD","LU1781817850.SGD","LU2488822045.USD","BK0012","LU2148510915.USD","HK0000320264.USD","LU1997245177.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184389225","title":"Hong Kong Market Analysis: Longxun's IPO Valuation Sets Benchmark, Stirring Tech Sector; \"Lab Monkey\" Prices Drive CXO Surge","url":"https://stock-news.laohu8.com/highlight/detail?id=1184389225","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184389225?lang=en_us&edition=fundamental","pubTime":"2026-07-15 20:43","pubTimestamp":1784119436,"startTime":"0","endTime":"0","summary":"The Hong Kong market has recently shown signs of moving independently, with its current trend aligning well with its internal structure. While the A-share market declined, Hong Kong stocks have...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1516","LU2488822045.USD","LU1235295612.USD","BK1147","LU2097828474.EUR","LU1046422090.SGD","BK1501","SG9999002828.SGD","SG9999003461.SGD","LU2328871848.SGD","BK1103","03908","HK0000306685.HKD","CXO","LU0390135332.USD","LU0049112450.USD","LU1969619763.USD","LU0359201612.USD","BK1589","LU0390135688.USD","LU0502904849.HKD","VXUS","06066","LU0359202008.SGD","LU0390135506.SGD","01801","LU0359201885.HKD","02343","HK0000500386.USD","LU2242644610.SGD","LU0300738514.USD","HK0000306701.USD","LU2097828714.EUR","HK0000252160.HKD","LU0300738605.USD","KCAI","BK4585","LU2097828631.EUR","HK0000320223.HKD","BK1161","BK1564","BK1535","KURE","BK4588","BK1583","HK0000252152.HKD","SG9999011746.SGD","IPOS","LU1023057109.AUD","LU2097828805.USD","SG9999001093.SGD","06127","SG9999002950.SGD","HK0000165453.HKD","02696","HK0000320264.USD","LU0455707207.USD","BK1576","LU2097828557.USD","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188098063","title":"HENLIUS's Global Drug H Gains Momentum, Accelerating Commercial Value Realization","url":"https://stock-news.laohu8.com/highlight/detail?id=1188098063","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188098063?lang=en_us&edition=fundamental","pubTime":"2026-07-13 16:10","pubTimestamp":1783930252,"startTime":"0","endTime":"0","summary":"The global commercial strategy for HENLIUS's key oncology drug is progressing rapidly, with its value increasingly recognized in international markets.At the recent \"First Gastric Cancer...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696","HK0000306685.HKD","HK0000320223.HKD","HK0000165453.HKD","HK0000306701.USD","HK0000320264.USD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650518161","title":"Shanghai Henlius Biotech's Cancer Drug Combination Trial Gets IND Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2650518161","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650518161?lang=en_us&edition=fundamental","pubTime":"2026-07-10 18:12","pubTimestamp":1783678326,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech (HKG:2696) said its investigational new drug application for a Phase I clinical trial of HLX37 in combination with chemotherapy or HLX43 has been approved by China's National ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4581","HK0000165453.HKD","XBI","02696","HK0000306701.USD","HK0000320264.USD","HK0000306685.HKD","BK1161","HK0000320223.HKD","BK4585","BK4588","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126218869","title":"HENLIUS secures NMPA green light for Phase 1 study of bispecific antibody HLX37 with chemotherapy or ADC HLX43 in advanced solid tumours","url":"https://stock-news.laohu8.com/highlight/detail?id=1126218869","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126218869?lang=en_us&edition=fundamental","pubTime":"2026-07-10 16:45","pubTimestamp":1783673101,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech, Inc. (HENLIUS, 02696.HK) disclosed that China’s National Medical Products Administration (NMPA) has approved its investigational new drug (IND) application to initiate a...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650839901","title":"Shanghai Henlius Says China NMPA Clears Phase 1 Trial of HLX37 with Chemo or HLX43 in Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2650839901","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650839901?lang=en_us&edition=fundamental","pubTime":"2026-07-10 16:31","pubTimestamp":1783672260,"startTime":"0","endTime":"0","summary":"Shanghai Henlius says China NMPA clears Phase 1 trial of HLX37 with chemo or HLX43 in solid tumorsChina’s NMPA cleared an IND for a Phase 1 trial of Henlius’ HLX37 in advanced or metastatic solid tumo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260710:nNDL1M63R0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000320264.USD","HK0000320223.HKD","02696","HK0000306701.USD","BK1230","BK1161","HK0000306685.HKD","00656","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650183640","title":"Shanghai Henlius Biotech - Nmpa Approves Ind for Phase 1 Trial of Hlx37 with Chemotherapy or Hlx43","url":"https://stock-news.laohu8.com/highlight/detail?id=2650183640","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650183640?lang=en_us&edition=fundamental","pubTime":"2026-07-10 16:30","pubTimestamp":1783672247,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260710:nFWN43C0E9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HK0000165453.HKD","HK0000320264.USD","BK1161","HK0000320223.HKD","HK0000306685.HKD","HK0000306701.USD","02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649299311","title":"Henlius Biotech Doses First Patient in Colorectal Cancer Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2649299311","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649299311?lang=en_us&edition=fundamental","pubTime":"2026-07-08 19:50","pubTimestamp":1783511447,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech (HKG:2696) dosed the first patient in a phase 1 clinical trial of cetuximab injection biosimilar HLX05-N.The drug is being tested in patients with metastatic colorectal cancer in Mainland China, according to a Wednesday Hong Kong bourse filing.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4581","HK0000306685.HKD","HK0000320264.USD","02696","HK0000320223.HKD","BK4585","BK1161","BK4588","HK0000165453.HKD","HK0000306701.USD","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122606361","title":"HENLIUS Initiates First Patient Dosing in China for Phase 1 Study of Cetuximab Biosimilar HLX05-N in Metastatic Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=1122606361","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122606361?lang=en_us&edition=fundamental","pubTime":"2026-07-08 17:32","pubTimestamp":1783503169,"startTime":"0","endTime":"0","summary":"HENLIUS (ASX: 02696) has announced that the first patient in China (excluding Hong Kong, Macau, and Taiwan) has been dosed in a Phase 1 clinical study of its self-developed cetuximab injection...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2272731865.HKD","LU2272731782.SGD","LU2473716301.USD","XPH","LU2272731600.USD","BK1161","BK4588","BK4585","02696","LU2322448791.USD","HK0000306701.USD","HK0000165453.HKD","LU2322448957.HKD","IBB","HK0000320264.USD","LU1992135399.USD","LU1992135472.HKD","HK0000306685.HKD","PPH","IE00B5TLWC47.USD","HK0000320223.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649896417","title":"Shanghai Henlius Doses First Patient in Phase 1 Trial of Cetuximab Biosimilar Hlx05-n in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2649896417","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649896417?lang=en_us&edition=fundamental","pubTime":"2026-07-08 17:25","pubTimestamp":1783502704,"startTime":"0","endTime":"0","summary":"Shanghai Henlius doses first patient in Phase 1 trial of cetuximab biosimilar HLX05-N in ChinaShanghai Henlius dosed the first patient in a Phase 1 mainland China trial of HLX05-N, a biosimilar of cet","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260708:nNDLb08kvy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1989764748.USD","BK4585","BK1161","LU0130518102.USD","HK0000306685.HKD","LU0130103400.USD","LU1791710400.SGD","HK0000320223.HKD","LU0477156797.USD","LU1791710582.SGD","BK4121","IQV","LU0130517989.USD","LU0477156953.USD","HK0000165453.HKD","EKG","HEAL","LU0980610538.SGD","LU0130102774.USD","LU1261432733.SGD","LU0528227936.USD","LU0198837287.USD","BK4530","LU0648000940.SGD","LU1989764664.SGD","LU0648001328.SGD","BK4588","HK0000320264.USD","LU1201861249.SGD","HK0000306701.USD","BK1230","02696","LU1201861165.SGD","LU0882574055.USD","00656"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197533999","title":"HENLIUS Adds 1.71 Million H-Shares in June; Option and RSU Schemes Drive Issuance","url":"https://stock-news.laohu8.com/highlight/detail?id=1197533999","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197533999?lang=en_us&edition=fundamental","pubTime":"2026-07-06 17:24","pubTimestamp":1783329842,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech, Inc. (HENLIUS) filed its monthly return for the period ended 30 June 2026, detailing an increase in both authorised and issued share capital driven by employee incentive...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648502163","title":"Is Shanghai Henlius Biotech (SEHK:2696) Pricey Or Undervalued After Its Canada Denosumab Launch?","url":"https://stock-news.laohu8.com/highlight/detail?id=2648502163","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648502163?lang=en_us&edition=fundamental","pubTime":"2026-07-02 19:47","pubTimestamp":1782992822,"startTime":"0","endTime":"0","summary":"Canadian denosumab launch puts Shanghai Henlius Biotech in focus\nShanghai Henlius Biotech (SEHK:2696) is drawing attention after announcing that its denosumab biosimilars BILDYOS and TUZEMTY are now available in Canada through partner Organon, covering all indications of the reference products.\nThe launch extends Henlius’s reach beyond its primarily China based revenue by bringing its osteoporosis and oncology supportive care portfolio into a mature biologics market, where Organon holds...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2696/shanghai-henlius-biotech-shares/news/is-shanghai-henlius-biotech-sehk2696-pricey-or-undervalued-a","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2696/shanghai-henlius-biotech-shares/news/is-shanghai-henlius-biotech-sehk2696-pricey-or-undervalued-a","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4588","DCF","HK0000320264.USD","BK4581","HK0000306701.USD","XBI","HK0000306685.HKD","02696","BK1161","HK0000320223.HKD","HK0000165453.HKD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119969085","title":"Henlius Shares Surge in Early Trading Following NHS Inclusion Recommendation for Cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=1119969085","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119969085?lang=en_us&edition=fundamental","pubTime":"2026-07-02 11:18","pubTimestamp":1782962305,"startTime":"0","endTime":"0","summary":"HENLIUS (SEHK: 02696) shares experienced a significant rise of nearly 12% during the morning trading session.At the time of reporting, the stock was up 7.07%, trading at HK$68.95 with a turnover of...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NICE","BK4566","BK4023","IE00BFMHRM44.USD","HK0000320264.USD","VXUS","HK0000306701.USD","BK4543","BK4585","HK0000165453.HKD","HK0000320223.HKD","HK0000306685.HKD","BK4588","02696","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168355373","title":"HENLIUS doses first patient in Phase 1 trial of bispecific ADC HLX48 for advanced solid tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=1168355373","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168355373?lang=en_us&edition=fundamental","pubTime":"2026-06-30 17:23","pubTimestamp":1782811396,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech, Inc. (HENLIUS) has initiated patient dosing in a first-in-human Phase 1 clinical study of HLX48, an antibody–drug conjugate (ADC) that simultaneously targets EGFR and c-MET,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647539433","title":"Shanghai Henlius Doses First Patient in Phase 1 HLX48 Trial for Advanced Solid Tumors in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2647539433","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647539433?lang=en_us&edition=fundamental","pubTime":"2026-06-30 17:14","pubTimestamp":1782810881,"startTime":"0","endTime":"0","summary":"Shanghai Henlius doses first patient in Phase 1 HLX48 trial for advanced solid tumors in ChinaShanghai Henlius Biotech dosed the first patient in a first-in-human Phase 1 study of HLX48, a bispecific ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nNDL6rZ3PM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000306701.USD","HK0000320223.HKD","BK1161","HK0000165453.HKD","BK1230","02696","HK0000320264.USD","00656","HK0000306685.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143959790","title":"HENLIUS Shares Surge Over 13% on EU Approval for New Lung Cancer Indication of H Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=1143959790","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143959790?lang=en_us&edition=fundamental","pubTime":"2026-06-29 10:44","pubTimestamp":1782701061,"startTime":"0","endTime":"0","summary":"Shares of HENLIUS (02696) surged more than 13% during the morning trading session. At the time of writing, the stock was up 13.33% to HK$62.9, with a turnover of HK$34.75 million.The significant...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VXUS","FSXEmain","HK0000320264.USD","HK0000306701.USD","FESXmain","HK0000320223.HKD","HK0000306685.HKD","BK1161","HK0000165453.HKD","BK4585","02696","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0286},{"period":"1month","weight":-0.1095},{"period":"3month","weight":-0.3221},{"period":"6month","weight":-0.0435},{"period":"1year","weight":-0.1081},{"period":"ytd","weight":-0.0167}],"compareEarnings":[{"period":"1week","weight":0.0163},{"period":"1month","weight":0.0662},{"period":"3month","weight":-0.0391},{"period":"6month","weight":-0.0668},{"period":"1year","weight":-0.0274},{"period":"ytd","weight":-0.026}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Shanghai Henlius Biotech Inc is a China-based company principally engaged in biopharmaceutical research and development, biopharmaceutical services and biopharmaceutical production and sales. The Company’s main products include HANQUYOU (trastuzumab for injection), HANNAIJIA (neratinib maleate), HANSIZHUANG (serplulimab injection), HANLIKANG (rituximab injection), HANDAYUAN (adalimumab injection), HANBEITAI (bevacizumab injection) and others. The Company’s products are mainly used in the treatment of adjuvant breast cancer, metastatic breast cancer, metastatic gastric cancer, metastatic non-squamous non-small cell lung cancer, polyarticular juvenile idiopathic arthritis and others. The Company mainly operates its businesses in the domestic and overseas markets.","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.044394},{"month":2,"riseRate":0.714286,"avgChangeRate":0.117695},{"month":3,"riseRate":0.571429,"avgChangeRate":-0.008815},{"month":4,"riseRate":0.857143,"avgChangeRate":0.12138},{"month":5,"riseRate":0.428571,"avgChangeRate":-0.033714},{"month":6,"riseRate":0.571429,"avgChangeRate":0.085211},{"month":7,"riseRate":0.428571,"avgChangeRate":0.041125},{"month":8,"riseRate":0.5,"avgChangeRate":-0.024213},{"month":9,"riseRate":0,"avgChangeRate":-0.127435},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.025526},{"month":11,"riseRate":0.571429,"avgChangeRate":0.058675},{"month":12,"riseRate":0.714286,"avgChangeRate":-0.023816}],"exchange":"SEHK","name":"HENLIUS","nameEN":"HENLIUS"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"HENLIUS(02696),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest HENLIUS(02696) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"HENLIUS,02696,HENLIUS股票,HENLIUS股票老虎,HENLIUS股票老虎国际,HENLIUS行情,HENLIUS股票行情,HENLIUS股价,HENLIUS股市,HENLIUS股票价格,HENLIUS股票交易,HENLIUS股票购买,HENLIUS股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"HENLIUS(02696),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest HENLIUS(02696) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}